Ying Su

987 total citations · 1 hit paper
22 papers, 500 citations indexed

About

Ying Su is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Gastroenterology. According to data from OpenAlex, Ying Su has authored 22 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Gastroenterology. Recurrent topics in Ying Su's work include Gastrointestinal Tumor Research and Treatment (7 papers), Gastrointestinal disorders and treatments (4 papers) and Ferroptosis and cancer prognosis (4 papers). Ying Su is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (7 papers), Gastrointestinal disorders and treatments (4 papers) and Ferroptosis and cancer prognosis (4 papers). Ying Su collaborates with scholars based in China, United States and Canada. Ying Su's co-authors include Xiaohong Chen, Dan Li, Xiaoyi Lv, Wenjia Guo, Chen Chen, Cheng Chen, Rodrigo Ruiz‐Soto, Rui Gao, Margaret von Mehren and Suzanne George and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Ying Su

21 papers receiving 492 citations

Hit Papers

Colon cancer diagnosis and staging classification based o... 2022 2026 2023 2024 2022 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Colon cancer diagnosis and staging classification based on machine learning and bioinformatics analysis
    2022 125 citations Ying Su, Rui Gao et al. Computers in Biology and Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ying Su China 8 242 176 121 96 79 22 500
Zixuan Cheng China 11 263 1.1× 65 0.4× 397 3.3× 28 0.3× 34 0.4× 30 530
M. Fang China 4 363 1.5× 98 0.6× 408 3.4× 54 0.6× 42 0.5× 7 620
Shigenaga Matsui Japan 13 360 1.5× 210 1.2× 108 0.9× 57 0.6× 73 0.9× 38 674
E Erbstösser Germany 5 118 0.5× 99 0.6× 50 0.4× 46 0.5× 36 0.5× 8 375
Shi‐Lun Cai China 18 425 1.8× 174 1.0× 89 0.7× 142 1.5× 21 0.3× 44 730
Chaoran Yu China 19 318 1.3× 84 0.5× 59 0.5× 281 2.9× 38 0.5× 47 862
Yasuharu Maeda Japan 15 331 1.4× 185 1.1× 231 1.9× 24 0.3× 104 1.3× 58 929

Countries citing papers authored by Ying Su

Since Specialization
Citations

This map shows the geographic impact of Ying Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Su more than expected).

Fields of papers citing papers by Ying Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Su. The network helps show where Ying Su may publish in the future.

Co-authorship network of co-authors of Ying Su

This figure shows the co-authorship network connecting the top 25 collaborators of Ying Su. A scholar is included among the top collaborators of Ying Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Su. Ying Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
He, Xiaoqian, Ying Su, Pei Liu, et al.. (2023). Machine learning-based immune prognostic model and ceRNA network construction for lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology. 149(10). 7379–7392. 3 indexed citations
2.
Su, Ying, et al.. (2023). A Prognostic Model of Genetic Markers for Triple-Negative Breast Cancer Based on Machine Learning and Bioinformatics Analysis. Studies in health technology and informatics. 308. 303–312. 3 indexed citations
3.
Li, Chenxi, et al.. (2023). A PRISMA meta-analysis for diagnostic value of microRNA-21 in head and neck squamous cell carcinoma along with bioinformatics research. Oral and Maxillofacial Surgery. 28(2). 739–752. 2 indexed citations
4.
Bauer, Sebastian, Robin L. Jones, Jean‐Yves Blay, et al.. (2022). Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology. 40(34). 3918–3928. 61 indexed citations
5.
Su, Ying, Rui Gao, Wenjia Guo, et al.. (2022). Colon cancer diagnosis and staging classification based on machine learning and bioinformatics analysis. Computers in Biology and Medicine. 145. 105409–105409. 125 indexed citations breakdown →
6.
Liu, Pei, Wenjia Guo, Ying Su, et al.. (2022). Multi-Omics Analysis of GNL3L Expression, Prognosis, and Immune Value in Pan-Cancer. Cancers. 14(19). 4595–4595. 7 indexed citations
7.
Yu, Jinghua, Wenyan Zhang, Xiang-Ling Meng, et al.. (2022). Regulation of host factor γ-H2AX level and location by enterovirus A71 for viral replication. Virulence. 13(1). 241–257. 3 indexed citations
8.
Heinrich, Michael C., Robin L. Jones, Hans Gelderblom, et al.. (2022). INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib. Journal of Clinical Oncology. 40(36_suppl). 359881–359881. 16 indexed citations
9.
George, Suzanne, Ping Chi, Michael C. Heinrich, et al.. (2021). Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. European Journal of Cancer. 155. 236–244. 22 indexed citations
10.
Bauer, Sebastian, Michael C. Heinrich, Suzanne George, et al.. (2021). Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clinical Cancer Research. 27(23). 6333–6342. 33 indexed citations
11.
Yu, Jinghua, Chunyu Liu, Ting Wu, et al.. (2020). Caspase-3 inhibitor inhibits enterovirus D68 production. The Journal of Microbiology. 58(9). 812–820. 7 indexed citations
12.
Su, Ying, Dan Li, & Xiaohong Chen. (2020). Lung Nodule Detection based on Faster R-CNN Framework. Computer Methods and Programs in Biomedicine. 200. 105866–105866. 109 indexed citations
13.
Zhang, Shuxia, Xiaoyan Yu, Xiang-Ling Meng, et al.. (2020). Coxsackievirus A6 Induces Necroptosis for Viral Production. Frontiers in Microbiology. 11. 42–42. 10 indexed citations
14.
Jankú, Filip, Albiruni R. Abdul Razak, Ping Chi, et al.. (2020). Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. Journal of Clinical Oncology. 38(28). 3294–3303. 70 indexed citations
15.
Liu, Chunyu, Fei Wang, Bin Wang, et al.. (2020). Pseudolaric acid B induces apoptosis in human rhabdomyosarcoma RD cells. Oncology Letters. 20(6). 1–1. 4 indexed citations
16.
Chi, Ping, Filip Jankú, Michael C. Heinrich, et al.. (2019). Abstract C077: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036). Molecular Cancer Therapeutics. 18(12_Supplement). C077–C077. 3 indexed citations
17.
George, Suzanne, Michael C. Heinrich, Albiruni Ryan Abdul Razak, et al.. (2018). Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.. Journal of Clinical Oncology. 36(15_suppl). 11511–11511. 2 indexed citations
18.
Lin, Selena Y., et al.. (2013). Abstract 1158: Detection of clonally expanded HBV DNA integration sites as a marker for early detection of HBV related HCC.. Cancer Research. 73(8_Supplement). 1158–1158. 1 indexed citations
19.
Li, Hong, Yi Shu, Yongjun Chen, et al.. (2009). Effects of hydralazine and valproate on the expression of E-cadherin gene and the invasiveness of QBC939 cells. Frontiers of Medicine in China. 3(2). 153–157. 5 indexed citations
20.
Li, Hong, Yi Shu, Yongjun Chen, et al.. (2008). Synergy of DNA methylation and histone deacetylase inhibitors in the re-expression of RASSF1A and P16 genes silenced in QBC cells. The Chinese-German Journal of Clinical Oncology. 7(11). 627–630. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zixuan Cheng Breakdown of academic impact, for papers by M. Fang Breakdown of academic impact, for papers by Shigenaga Matsui Breakdown of academic impact, for papers by E Erbstösser Breakdown of academic impact, for papers by Shi‐Lun Cai Breakdown of academic impact, for papers by Chaoran Yu Breakdown of academic impact, for papers by Yasuharu Maeda
Rankless by CCL
2026